Peginterferon Alfa-2a, Lamivudine, and the Combination for HBeAg-Positive Chronic Hepatitis B | Zendy

George Lau | Zendy; Teerha Piratvisuth | Zendy; Kang Luo | Zendy; Patrick Marcellin | Zendy; Satawat Thongsawat | Zendy; Graham Cooksley | Zendy; Edward Gane | Zendy; Michael Fried | Zendy; Wan Cheng Chow | Zendy; Seung Woon Paik | Zendy; Wen Yu Chang | Zendy; Thomas Berg | Zendy; Robert Flisiak | Zendy; Philip McCloud | Zendy; N. Pluck | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Peginterferon Alfa-2a, Lamivudine, and the Combination for HBeAg-Positive Chronic Hepatitis B

Author(s) -

George Lau,

Teerha Piratvisuth,

Kang Luo,

Patrick Marcellin,

Satawat Thongsawat,

Graham Cooksley,

Edward Gane,

Michael Fried,

Wan Cheng Chow,

Seung Woon Paik,

Wen Yu Chang,

Thomas Berg,

Robert Flisiak,

Philip McCloud,

N. Pluck

Publication year - 2005

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa043470

Subject(s) - lamivudine , medicine , gastroenterology , hbeag , hbsag , peginterferon alfa 2a , seroconversion , pegylated interferon , adverse effect , alpha interferon , hepatitis b , interferon alfa , hepatitis b virus , interferon , virology , chronic hepatitis , virus , ribavirin

Current treatments for chronic hepatitis B are suboptimal. In the search for improved therapies, we compared the efficacy and safety of pegylated interferon alfa plus lamivudine, pegylated interferon alfa without lamivudine, and lamivudine alone for the treatment of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research